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Abstract
Aim
Fatigue is the most commonly reported symptom of Hepatitis C Virus (HCV) infected
patients and severely impacts their quality of life. The aim of this study was to measure the
impact of 3D regimen treatment on the fatigue, daytime physical activity and sleep efficiency
of HCV infected patients with fatigue.
Methods
HEMATITE was an observational, prospective, open-label, single-arm, Swiss multi-centric
study in mono-infected HCV genotype 1 patients. The 28 week observation period com-
prised of 4 weeks preparation, 12 weeks treatment and 12 weeks follow-up. Fatigue was
assessed using the fatigue severity scale (FSS) questionnaire. Patients with FSS� 4 (clini-
cally significant fatigue) were included. The activity tracker, ActiGraph GT9X Link®, was
used to measure daytime physical activity and sleep efficiency. Outcome analysis was per-
formed on a scaled down intention to treat (sdITT) population, which excluded patients with
insufficient tracker data at all study visits and a modified ITT (mITT) population, which con-
sisted of patients with complete tracker data at all study visits.
Results
Forty of 41 patients in the ITT population had a sustained virologic response 12 weeks post-
treatment (SVR12). Mean baseline FSS score was 6.0 for the sdITT population and 5.9 for
the mITT population and decreased from baseline to 12 weeks post-treatment by 2.6 (95%
confidence interval [CI]: 2.1, 3.1) for the sdITT (n = 37) population and 2.8 (95% CI: 2.2, 3.4)
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for the mITT (n = 24) population. Mean daytime physical activity or sleep efficiency did not
change considerably over the course of the study.
Conclusion
Measurement by the activity tracker of mean day time physical activity did not show a con-
siderable change from baseline to SVR12 upon treatment with 3D regimen. Nevertheless, a
reduction of fatigue as assessed with the validated fatigue severity scale (FSS) was
observed, suggesting a causative role of HCV in this extrahepatic manifestation.
Trial registration
ClinicalTrials.gov identifier: NCT03002818.
Introduction
Chronic hepatitis C virus (HCV) infection, characterized by persistent hepatic inflammation,
affects around 71 million people worldwide and can lead to liver fibrosis, cirrhosis and hepato-
cellular carcinoma [1]. Extrahepatic systems, such as the central nervous system (CNS), are
also associated with chronic HCV, and neuropsychiatric disorders are more prevalent among
HCV infected patients than the general population [2–4]. The reason for this is manifold:
HCV infected patients are more likely to have pre-existing mental illness or to abuse psychoac-
tive substances [5]; cirrhosis may lead to minimal or overt encephalopathies with a broad
range of neuropsychological symptoms [6]; pharmaceutical treatment for HCV can exacerbate
certain neuropsychiatric symptoms [7]; and HCV itself may have a direct biologic effect on the
CNS [8].
HCV infected patients may present with many neuropsychiatric disorders including
fatigue, anxiety, depression and cognitive impairment, which can significantly reduce their
quality of life [3, 9–12]. Of these, fatigue is the most commonly reported symptom [10, 13, 14]
and may occur in conjunction with sleep disturbances [15]. Reduced quality of life in HCV
infected patients is independent of liver damage [13]. HCV eradication following treatment
with interferon alpha and ribavirin has been shown to improve neurocognitive symptoms in
patients [16].
Treatment of HCV has progressed in recent years with the approval of 3D regimen, an
interferon-free regimen indicated in HCV genotype 1 infected patients. It has been shown to
result in high rates of sustained virologic response 12 weeks post-treatment (SVR12) [17, 18].
The treatment consists of paritaprevir, a protease inhibitor boosted by ritonavir; ombitasvir, a
HCV nonstructural protein 5A (NS5A) replication complex inhibitor; and dasabuvir, a non-
nucleoside RNA polymerase inhibitor. To date, there has been only few publications on the
characterization of fatigue through treatment with newly developed direct-acting antivirals
[19], and no research into the effect of 3D regimen on the quality of life of HCV patients suf-
fering from fatigue. A recently published work of Durcan et al. found, that direct antivirals did
not lead to depression, anxiety or fatigue and did not decrease liver-specific quality of life [20].
The aim of this observational study, HEMATITE, was to measure the impact of 3D regimen
on the daytime physical activity, fatigue and sleep efficiency of HCV patients with fatigue.
Patients with predisposing factors of fatigue, such as severe depression, cirrhosis and cancer
were excluded from the study.
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Materials and methods
Study design
HEMATITE was a single-arm, prospective, post-marketing, observational study in HCV
patients receiving 3D regimen according to routine clinical practice. The 28 week observation
period was comprised of 4 weeks preparation, 12 weeks treatment and 12 weeks follow-up. At
Study Visit 1 (Day -28; before treatment start), patient screening took place; at Study Visit 2
(Day 1; treatment start), baseline data were obtained; Study Visit 3 (Day 28) was an interim
visit; Study Visit 4 (Day 84) was at the end of treatment; and at Study Visit 5 (Day 168), SVR12
was assessed (S1 Fig). The study enrolled patients over a 12 month period and was conducted
at five HCV competence centers in Switzerland from Mar 2017 to Apr 2018: Kantonsspital
St. Gallen, St. Gallen; University Hospital Zürich, Zürich; Universitätsspital Bern, Bern; Fonda-
zione Epatocentro Ticino, Lugano and Hôpital Neuchâtelois Pourtalès, Neuchâtel. The proto-
col was approved by the Ethikkommission Ostschweiz, St. Gallen and conducted in
accordance with the Declaration of Helsinki. Written informed consent was obtained from all
participants included in the study.
Patients
Patients diagnosed with HCV, whom the physician had already decided to treat with 3D regi-
men, were offered the opportunity to participate in the study. Patients were eligible if they
were aged 18 years or older, were mono-infected with chronic HCV genotype 1, had fatigue
(fatigue severity scale [FSS]� 4 [21]), were treatment naïve and did not have liver cirrhosis.
Patients were excluded if they had fatigue from sources other than HCV (e.g. severe depres-
sion, cancer and hormonal disorders), had conditions that did not allow them to adhere to the
protocol or were wheelchair dependent.
Treatment
Commercially available 3D regimen, i.e. ombitasvir, paritaprevir and ritonavir tablets (Vie-
kirax1, AbbVie Deutschland GmbH & Co. KG, Germany) and dasabuvir tablets (Exviera1,
AbbVie Deutschland GmbH & Co. KG, Germany), was used as per routine clinical practice,
local label and guidelines. The treatment regimen was at the discretion of the physician and
was decided upon prior to offering the patient the opportunity to participate in the study.
Fatigue severity scale
Fatigue was assessed at baseline (Day 1), Day 28, Day 84 and 12 weeks post-treatment (Day
168) using the FSS questionnaire which has been validated for use in chronic HCV and is an
adequate measure of fatigue outcomes in HCV clinical trials [21]. Patients answered nine ques-
tions using a scale from one (strongly disagree = 1 point) to seven (strongly agree = 7 points)
(S2 Fig). A fatigue score was obtained by calculating the mean score of the nine items. The
higher the score (with a maximum of 7), the greater the fatigue. Clinically significant fatigue
was defined as a score equal or above four [21, 22].
Activity tracker
The activity tracker, ActiGraph GT9X Link1 (ActiGraph LLC, Pensacola, Florida, USA), was
used to measure daytime physical activity and sleep efficiency. ActiGraph GT9X Link1 is a
Class I medical device within the European Union [23] and ActiGraph1 devices have been
used in several research studies and clinical trials to measure physical activity, energy expendi-
ture and sleep/wake behavior [24–26]. Patients wore the activity trackers on their non-
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dominant arm for 4 weeks prior to each study visit (baseline [Day 1], Day 28, Day 84 and 12
weeks post-treatment [Day 168]). The patients were instructed on the use of the device by
study personnel and were reminded when to put it on. The daytime physical activity was
recorded by the activity tracker in counts. Counts were the sum of accelerometer values (raw
data at 30 Hz) that had passed through a proprietary filtering process to eliminate non-human
movement. Sleep efficiency was also recorded by the activity tracker and was defined as the
percentage of time scored as sleep during the sleep period. At 12 weeks post-treatment (Day
168), tracker data collected using device specific software (ActiSync) were processed by the
biostatistician. The data were not visible to the Investigator or patients during the study.
Patient characteristics, vital signs and laboratory parameters
Patient data (demographics, disease characteristics, comorbidities, concomitant medication
and treatment details) were obtained from the patient’s medical records.
Vital signs (blood pressure, pulse, weight and height, body mass index [BMI] and tempera-
ture) and laboratory parameters (HCV RNA level, alanine aminotransferase, aspartate amino-
transferase, total bilirubin, hemoglobin, creatinine, ferritin, thyroid stimulating hormone,
fasting glucose and human chorionic gonadotropin) were measured at each study visit.
Variables
The primary outcome variable was a change in mean daytime physical activity from baseline
(Day 1) to 12 weeks post-treatment (Day 168). The secondary variables were a change in FSS
score from baseline (Day 1) to 12 weeks post-treatment (Day 168); a correlation between mean
daytime physical activity and FSS score from baseline (Day 1) to 12 weeks post-treatment (Day
168); sleep efficiency at baseline (Day 1), during and after 12 weeks post-treatment (Day 168);
and the proportion of patients who achieved SVR12.
Statistical methods
A sample size of 100 was planned, which would have had 80% power to detect a change from
baseline of the effect size 0.29 using a two-sided one-sample t-test with a significance level of
5%. However, the anticipated sample size was not met. The main reasons for this were the
launches of new pangenotypic treatment options and the abolition of a limitatio laid down by
the Swiss Federal Office of Public Health.
Safety analysis was performed on the intention to treat (ITT) population which comprised
all patients who received the study treatment at least once. Outcome analysis was performed
on the following two populations: the scaled down ITT (sdITT) population, defined as the ITT
population minus patients who discontinued or were excluded because of missing or insuffi-
cient tracker data at all study visits, and the modified ITT (mITT) population, defined as
patients in the sdITT population who had complete tracker data at all five study visits.
Activity tracker data for 10 working days before each scheduled study visit (baseline [Day
1], Day 28, Day 84 and 12 weeks post-treatment [Day 168]) were used to calculate the mean
daytime physical activity and sleep efficiency for each tracker phase of the study. Days
missing� 2 hours activity data during the daytime (as determined by a built-in wear time sen-
sor) were excluded. Data for these days were replaced by daytime values in a pre-defined
order, starting with the most recent day of the preceding week.
Data for each study visit were analyzed using descriptive statistical analysis. For daytime physi-
cal activity, FSS and sleep efficiency, the mean change and the 95% confidence interval (CI)
between baseline (Day 1) and Day 28, Day 84 and 12 weeks post-treatment (Day 168) was calcu-
lated. The difference between mean physical activity at baseline (Day 1) and at 12 weeks post-
PLOS ONE HCV patient quality of life with 3D regimen
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treatment (Day 168) was analyzed by a two-sided one-sample t-test with a significance level of α =
0.05. The correlation between mean daytime physical activity and FSS score was analyzed by
Spearman’s rank correlation coefficient. The proportion of patients who achieved SVR12 and the
95% CI were also calculated as standard Wald intervals using the estimated standard error.
Subgroup analysis was performed to assess the effect of the following factors on daytime
physical activity, FSS and sleep efficiency: concomitant ribavirin, gender, fibrosis stage, age
and genotype 1 subtype. Differences were determined by t-test or Mann-Whitney-U test with
a significance level of α = 0.05. All statistical analysis was performed using SPSS1 for Win-
dows, version 22.0.
Safety analysis
Safety assessments were performed in a standardized method at each study visit and included
the evaluation of adverse events (AEs): serious AEs (SAEs), severe AEs, treatment-related AEs,
procedure-related AEs (i.e. AEs associated with wearing the activity tracker) and AEs leading
to discontinuation. An increase in the FSS score by� 1 was also reported as an AE.
Results
Patients
The number of patients who participated in the study are shown in Fig 1. Forty-five patients
were screened, of whom 41 were eligible and received 3D regimen treatment at least once (ITT
population). The outcome analysis sdITT population comprised 37 patients and excluded
patients who discontinued (n = 1) or had missing tracker data for all study visits (n = 3). The
outcome analysis mITT population comprised 24 patients and excluded patients with partial
tracker data sets (n = 13).
The patient characteristics at screening are shown in Table 1. Patients had been diagnosed
with HCV infection an average of 14.0 (± 9.3) years before screening and were HCV treatment
naïve. The most reported (� 8.0%) conditions at screening were drug abuse (21.9%), asthenia
(9.8%), depression (9.8%), hepatic steatosis (9.8%) and hypertension (9.8%). Forty patients
completed the 3D regimen treatment.
Primary and secondary variables
Mean daytime physical activity (measured in day counts) decreased slightly but did not change
significantly over the course of the study (Fig 2). The mean baseline (Day 1) day counts was
1,469,569 for the sdITT population and 1,513,166 for the mITT population. The change from
baseline (Day 1) to 12 weeks post-treatment (Day 168) was -108,266 day counts (95% CI:
-235,037, 18,504) for the sdITT population (p = 0.091) and -98,373 day counts (95% CI:
-235,667, 38,921) for the mITT population (p = 0.152) (Fig 2A and 2B). There was no correla-
tion between daytime physical activity and FSS score over the course of the study as assessed
by Spearman’s rank correlation coefficient.
The distribution of FSS score from screening (Day -28) to 12 weeks post-treatment (Day
168) is shown in Fig 3 for both analysis populations. From screening (Day -28) to baseline
(Day 1), no change in FSS was observed (Fig 3A and 3B). The mean baseline (Day 1) FSS
score was 6.0 for the sdITT population and 5.9 for the mITT population. A reduction in fatigue
(i.e. a decrease in mean FSS score) was observed during the treatment period and was sus-
tained until 12 weeks post-treatment (SVR12) (Fig 3A, 3B and 3C). The FSS score decreased
from baseline (Day 1) to 12 weeks post-treatment (Day 168) by 2.6 (95% CI: 2.1, 3.1) for the
sdITT population and 2.8 (95% CI: 2.2, 3.4) for the mITT population (Fig 3D and 3E).
PLOS ONE HCV patient quality of life with 3D regimen
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Similar to daytime physical activity, sleep efficiency decreased slightly but did not change
considerably over the course of the study. The mean change in sleep efficiency from baseline
(Day 1) to treatment week 4 (day 28) was -0.87% (95% CI: -1.7, -0.03) for the sdITT population
and -0.44% (95% CI: -1.5, 0.6) for the mITT population. The mean change in sleep efficiency
from baseline (Day 1) to end of treatment (Day 84) was -0.06% (95% CI: -1.0, 0.9) for the
sdITT population and 0.01% (95% CI: -1.2, 1.2) for the mITT population. The mean change in
sleep efficiency from baseline (Day 1) to 12 weeks post-treatment (Day 168) was -0.6% (95%
CI: -0.7, 1.9) for the sdITT population and 0.7% (95% CI: -0.6, 2.1) for the mITT population.
The percentage of patients that reached SVR12 was 97.3% (95% CI: 92.3, 100.0) in the
sdITT population and 95.8% (95% CI: 88.3, 100.0) in the mITT population.
Subgroup analysis
Concomitant ribavirin, gender, fibrosis stage, age and genotype 1 subtype had no effect on
daytime physical activity, FSS score or sleep efficiency in the sdITT or mITT populations.
An analysis of several predictors to the three outcome variables daytime physical activity,
sleep efficiency and FSS were performed via generalized linear models with repeated measure-
ment. As predictors age (classified by median split:� 50 years/>50 years), gender (male/
female), HCV genotype (genotype 1a/genotype 1b), liver fibrosis (yes/no) and ribavirin use
(yes/no) were investigated, results are shown for sdITT population (S1 Table) and for mITT
population (S2 Table). Overall, for none of the analyzed possible predictive factors the univari-
ate as well as the multivariate analysis showed significance. The corresponding effect sizes
demonstrated no or very small effects for these factors. Therefore, the factors age class, sex,
Fig 1. Flow chart of study participants. ITT = intention to treat population; sdITT = scaled down ITT population; mITT = modified ITT
population.
https://doi.org/10.1371/journal.pone.0241267.g001
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fibrosis, HCV genotype and ribavirin use had no influence of the three outcome variables
mean daytime physical activity, sleep efficiency and FSS.
Safety
During the study, there were no SAEs, procedure-related AEs or AEs that led to disconti-
nuation. Twenty-one (51.2%) of 41 patients experienced an AE during the study. Thirteen
Table 1. Patient characteristics at screening.
Characteristic n/N (%)
Age [years], mean (± SD) 49.4 (± 12.7)
� 50 years 22/41 (53.7)
> 50 years 19/41 (46.3)
Gender
Male 14/41 (34.1)
Female 27/41 (65.9)
Race
Caucasian 41/41 (100.0)
BMI [kg/m2], mean (± SD) 23.7 (± 4.4)
BMI� 25 (overweight)� 11/32 (34.4)
Fibrosis stage
No fibrosis 15/41 (36.6)
F1 stage 26/41 (63.4)
Source of HCV infection†
IV drug use 18/41 (43.9)
Tattoos or piercings 5/41 (12.2)
Sexual transmission 3/41 (7.3)
Transfusions 3/41 (7.3)
Other 5/41 (12.2)
Unknown 13/41 (31.7)
HCV genotype
Genotype 1a 24/41 (58.5)
Genotype 1b 17/41 (41.5)
Smoking and alcohol consumption
Smokers 21/38 (55.3)
Consume alcohol 25/39 (64.1)
Laboratory markers, mean (± SD)
HCV RNA level [log10 IU/mL], n = 38 6.6 (± 6.8)
AST [U/L], n = 38 40.7 (± 21.0)
ALT [U/L], n = 38 48.0 (± 28.2)
Total bilirubin [μmol/L], n = 37 11.7 (± 6.3)
Hemoglobin [g/L], n = 26 (normal range: 120–180 g/L) 143.6 (± 15.0)
Creatinine [μmol/L], n = 38 (normal range: 44–106 μmol/L) 67.3 (± 12.9)
Ferritin [μg/L], n = 22 (normal range: 30–200 μg/L) 172.4 (± 130.4)
TSH [mU/L], n = 24 (normal range: 0.3–3.5 mU/L) 1.7 (± 1.3)
Fasting glucose [mmol/L], n = 26 (normal range: 3.9–5.6 mmol/L) 5.0 (± 0.6)
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BMI = body mass index; HCV = hepatitis C;
IV = intravenous; RNA = ribonucleic acid; SD = standard deviation; TSH = thyroid stimulating hormone.
† Multiple answers were reported
�BMI data only available for 32 patients
https://doi.org/10.1371/journal.pone.0241267.t001
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(31.7%) patients experienced at least one AE that was considered as treatment-related by the
Investigator. The most commonly reported AEs and treatment-related AEs are shown in
Table 2.
Fig 2. Change in mean daytime physical activity from baseline (Day 1) to Day 28, Day 84 and 12 weeks post-treatment (Day 168) is shown for (a) the sdITT population
and (b) the mITT population. ˚ = outlier (value maximum 1.5 to 3 fold box length); � = extreme value (> 3 fold box length); mITT = modified intention to treat;
sdITT = scaled down intention to treat; V = study visit.
https://doi.org/10.1371/journal.pone.0241267.g002
Fig 3. Distribution of mean FSS score at screening (Day -28), baseline (Day 1), Day 28, Day 84 and 12 weeks post-treatment (Day 168) is shown for (a) the sdITT
population, (b) the mITT population and (c) all patients that had a completed FSS questionnaire for all study visits (n = 39). The decrease in mean FSS score from
baseline (Day 1) to Day 28, Day 84 and 12 weeks post-treatment (Day 168) is shown for (d) the sdITT population and (e) the mITT population. ˚ = outlier (value
maximum 1.5 to 3 fold box length); FSS = fatigue severity scale, mITT = modified intention to treat; sdITT = scaled down intention to treat; V = study visit.
https://doi.org/10.1371/journal.pone.0241267.g003
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Discussion
This observational study examined the impact of treatment with 3D regimen on HCV patients
suffering from fatigue. Fatigue is experienced by over half of HCV patients [10, 13, 14] and is
one of a number of extrahepatic manifestations responsible for their reduced quality of life [2,
27]. In our study, patient fatigue was independent of gender, age and genotype 1 subtype. In
addition, patient fatigue seems to be independent of fibrosis stage, although our observation is
based on F0 and F1 patients exclusively. Moreover, fatigue could not be attributed to cirrhosis,
cancer, severe depression or prior-HCV treatment, as patients with these predisposing factors
were excluded from the study. This would indicate that HCV infection itself is most likely
responsible for fatigue; a finding that supports research by others [9, 28]. While it is not
known exactly how HCV causes fatigue and other neuropsychiatric disorders, it is thought
that the virus penetrates the CNS and causes neuroinflammation which results in alterations
in cerebral metabolism, immune activation and neurotransmission [29].
In this study, treatment with 3D regimen reduced fatigue over time in non-cirrhotic, treat-
ment naïve patients with HCV genotype 1 infection. A reduction in mean FSS score of 2.8
(95% CI: 2.21, 3.43) from baseline (Day 1) to 12 weeks post-treatment (Day 168) was observed
in the mITT population. This change was significant with p< 0.001, Friedman’s ANOVA.
This was a notable decrease considering that a mean FSS score difference of� 0.7 is consid-
ered clinically important [22]. All but one patient treated with 3D regimen achieved viral elim-
ination as determined by undetectable HCV RNA 12 weeks post-treatment (SVR12) resulting
in an SVR12 rate of> 97%. This high SVR12 achieved in a real life setting confirms previous
results from registered trials with 3D regimen [17, 30, 31]. In the patient who did not achieve
Table 2. Adverse events and treatment-related adverse events occurring in� 2.5% of patients (N = 41).
Adverse event † n (%)
Any AE ‡ 21 (51.2)
Any SAE 0 (0)
AEs leading to discontinuation 0 (0)
AEs occurring in � 2 patients
Nausea 6 (14.6)
Dizziness / vertigo 3 (7.3)
Anemia 2 (4.9)
Abdominal pain 2 (4.9)
Emesis 2 (4.9)
Epigastric pressure pain 2 (4.9)
Flu like symptoms 2 (4.9)
FSS increased� 1 2 (4.9)
Total bilirubin increase 2 (4.9)
Any treatment-related AE 13 (31.7)
Treatment-related AEs occurring in � 2 patients
Nausea 4 (9.8)
Total bilirubin increase 2 (4.9)
Anemia 2 (4.9)
FSS increased� 1 2 (4.9)
AE = adverse event; FSS = fatigue severity scale: SAE = serious adverse event.
† Fatigue is not included as it was part of the inclusion criteria. An increase of � 1 point in the FSS was documented
as an AE.
‡ Any AE occurred in 21 out of 41 patients (51.2%).
https://doi.org/10.1371/journal.pone.0241267.t002
PLOS ONE HCV patient quality of life with 3D regimen
PLOS ONE | https://doi.org/10.1371/journal.pone.0241267 November 4, 2020 9 / 13
SVR12, the FSS score decreased from baseline (Day 1) until end of treatment (Day 84) but
increased again at 12 weeks post-treatment (Day 168). There was no virology data available for
this patient at the end of treatment visit to determine if a corresponding decline in HCV RNA
occurred at this time point.
The accuracy of the validated FSS questionnaire was supported by the fact that no change
in FSS score was observed from screening (Day -28) to baseline (Day 1); FSS score only
decreased over the treatment period and was sustained until 12 weeks post-treatment
(SVR12).
Interestingly, fatigue reduction did not correlate with an increase in mean daytime physical
activity during the working week. Indeed, mean daytime activity during the working week did
not change during the course of treatment. This result may be partly explained by the fact that
a high proportion of jobs are sedentary and most working conditions do not allow for large
changes in physical activity. Similarly, sleep efficiency assessed by an activity tracker did not
improve over the course of the study. This is in line with the findings of Heeren et al., where
there was no correlation between the results of a fatigue questionnaire (fatigue impact scale)
and sleep actigraphy data in HCV patients observed and the authors suggested that bad sleep
quality may therefore not be associated with increased nocturnal motor activity [24].
This is the first study to use an activity tracker in HCV patients during a course of treat-
ment. While activity trackers are useful tools in monitoring physical activity and sedentary
behavior over time, these devices have some limitations. The accuracy of some activity trackers
is variable and they may over- or underestimate total activity [32]. Differences in physical
activity may be too small to be detected by the activity tracker and studies have shown that
they may not accurately detect light physical activity such as washing dishes, cooking food and
walking slowly [33]. For a device to accurately report on changes in daily activity, it must be
worn consistently [34]. This study had a particularly long tracking period which may have led
to study fatigue and inconsistent wearing of the tracking device resulting in missing data and
therefore data that were not representative of actual physical activity. Furthermore, wearing a
tracker may trigger physical activity in patients per se and thus may confound routine activity.
The relatively small patient number and the inclusion of only F0 and F1 patients further add to
the limitations of our study.
Differentiating between HCV-associated and non-associated fatigue, physical inactivity and
comorbidities is difficult. In our study, 34.4% of patients were overweight (BMI� 25), 64.1%
consumed alcohol and 55.3% were smokers at screening. These factors may have contributed
to fatigue and a lack of physical activity in patients during the study. In addition, there were
concomitant medications that may have exacerbated some of the neuropsychiatric symptoms
of HCV. In patients receiving concomitant sedative medication, there was no particular trend
in FSS score over the course of the study (S3 Fig). Interestingly, despite its hemolytic character-
istics and thus potential to cause anemia [35], co-administration of ribavirin did not impact
fatigue or physical activity. This is in line with previous reports characterizing health related
quality of life during co-administration of ribavirin and other direct-acting antivirals [36].
3D regimen was well-tolerated and the AE profile was in line with that previously reported
[17, 30]. In conclusion, treatment with 3D regimen reduced fatigue in treatment naïve geno-
type 1 mono-infected HCV patients over time. Thus, successful treatment may reduce the
physical burden of manifestations of HCV and improve the overall quality of life of patients.
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S1 Fig. Study design and schedule of assessments. The 28 week observation period was com-
prised of 4 weeks preparation, 12 weeks treatment and 12 weeks follow-up. Screening took
place at Day -28 (Study Visit 1). Fatigue was assessed by FSS questionnaire on Days 1, 28, 84
and 168 (Study Visits 2, 3, 4 and 5, respectively). Daytime physical activity and sleep efficiency
were assessed by activity tracker during 4 x 4 week tracker phases. Baseline data were collected
in tracker phase 1. A data set of 2 eligible weeks (10 working days) was used to assess daytime
physical activity and sleep efficiency from tracker phases 1, 2, 3 and 4. SVR12 was determined
on Day 168 (12 weeks post-treatment).
(TIF)
S2 Fig. Fatigue severity scale. Taken from Krupp LB, LaRocca NG,Muir-Nash J, Steinberg AD.
The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus ery-
thematosus. Arch Neurol 1989;46:1121–1123.
(TIF)
S3 Fig. Distribution of mean FSS score at screening (Day -28), baseline (Day 1), Day 28,
Day 84 and 12 weeks post-treatment (Day 168) is shown for all patients receiving sedative
medication (n = 11).
(TIF)
S1 Table. Possible predictors for the outcomes, sdITT (n = 37).
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